Compare ABUS & CPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | CPF |
|---|---|---|
| Founded | 2005 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.5M | 997.1M |
| IPO Year | 2008 | 2011 |
| Metric | ABUS | CPF |
|---|---|---|
| Price | $4.40 | $39.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.7M | 137.2K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 55.26 | 45.18 |
| EPS | ★ 0.87 | 0.78 |
| Revenue | $14,083,000.00 | ★ $51,817,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $239.71 | $4.62 |
| P/E Ratio | ★ $5.14 | $49.59 |
| Revenue Growth | ★ 128.21 | 33.81 |
| 52 Week Low | $3.25 | $25.62 |
| 52 Week High | $5.38 | $40.06 |
| Indicator | ABUS | CPF |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 58.72 |
| Support Level | $4.16 | $33.33 |
| Resistance Level | $4.69 | $39.63 |
| Average True Range (ATR) | 0.24 | 0.91 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 11.95 | 57.80 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.